Clinical Trial

Modulation of the Bone Immune Microenvironment Following Cabozantinib Treatment of Bone Metastatic Clear Cell Renal Cell Carcinoma: Proof of Concept Study

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
The goal of our study is to explore how treatments affect the bone immune microenvironment and determine the best treatment options for patients with metastatic kidney cancer to the bone. This could prevent skeletal complications and improve patient outcomes.
Protocol Amendment History 1 change
critical Recruitment opened 2026-08-12
Trial Details
NCT Number NCT07187869
Lead Sponsor M.D. Anderson Cancer Center
Collaborators: Exelixis
Conditions Clear Cell Renal Cell Carcinoma
Enrollment 16 participants
Start Date 2026-02-12
Primary Completion 2027-04-07 (estimated)
Study Completion 2029-04-07 (estimated)
Updated on ClinicalTrials.gov 2026-08-11